Vertex Pharmaceuticals Inc is a pioneering biotechnology firm focused on creating innovative treatments for cystic fibrosis (CF) and other serious diseases. It offers a range of CF therapies, including TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, targeting different age groups and genetic mutations. Beyond CF, Vertex is exploring treatments for pain, sickle cell disease, beta thalassemia, and Type 1 Diabetes through advanced clinical trials. Founded in 1989 and based in Boston, Massachusetts, Vertex collaborates with leading biotech entities to expand its therapeutic portfolio, aiming to address unmet medical needs.
Vertex Pharmaceuticals drops its Q2 2026 results tonight with a $10 billion acquisition just closed, a blockbuster pain drug launch in full swing, and analysts watching one kidney disease drug that could…
Thomas Richmond Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire…
CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech…
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave…
The death crosses flashing on both Hershey (NYSE: HSY | HSY Price Prediction) and Vertex Pharmaceuticals (NASDAQ: VRTX) are a bearish technical signal that Wall Street is openly ignoring. Analyst consensus on…
Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free cash, while Wall Street prices…
Alex Sirois If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading…
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR…
Saudi Aramco CEO Amin Nasser did not mince words on Tuesday. Speaking to reporters on an earnings call, he said: “The Iran war will have catastrophic consequences for the world’s oil market.”…
Pre-Market Futures: The futures are trading higher this morning after another stellar day across Wall Street on Tuesday, as all the major indices once again ended higher and continue to print new…
Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade. This level…
Buy-and-hold investing is a time-tested strategy that rewards patience and discipline. By owning high-quality stocks for at least three to five years, preferably a decade or more, investors can harness the power…
Pfizer (NYSE:PFE | PFE Price Prediction) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster…
The most notable insider purchases of the past week came from return buyers, including Warren Buffett. Another biotech IPO also tempted insiders to scoop up some shares.
Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices. Walmart (NYSE:WMT | WMT Price Prediction)…
